VivoSim Labs, Inc. (VIVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.58M
Last updated: Nov 17, 2026 at 11:05 AM ET
VivoSim Labs, Inc. (VIVS) Financials: Revenue, Profit and Cash Flow
VivoSim Labs reported revenue of $131.00K for the fiscal year ended Mar 31, 2026, down 9.0% from the year before. That year, net income was -$13.84M with a net margin of -10567.2%, operating cash flow was -$10.83M and free cash flow was -$10.83M. The quarter ended Sep 30, 2026 had revenue of $51.00K and net income of -$475.00K.
Revenue and Margins
Over the 9 years to Mar 2026, revenue fell from $4.23M, a compound annual decline of 32.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $131.00K | -9.0% | 100.0% | -8768.7% | -10567.2% |
| Mar 2025 | $144.00K | +32.1% | 96.5% | -8761.1% | -1727.8% |
| Mar 2024 | $109.00K | -70.5% | 100.0% | -13840.4% | -13459.6% |
| Mar 2023 | $370.00K | -75.3% | 100.0% | -4792.2% | -4664.6% |
| Mar 2022 | $1.50M | N/A | 100.0% | -765.3% | -763.2% |
| Mar 2021 | $0 | -100.0% | N/A | N/A | N/A |
| Mar 2020 | $2.20M | -29.0% | 85.1% | -977.9% | -852.0% |
| Mar 2019 | $3.09M | -32.8% | 84.4% | -882.4% | -861.7% |
| Mar 2018 | $4.60M | +8.8% | 77.6% | -766.3% | -756.1% |
| Mar 2017 | $4.23M | N/A | 77.4% | -911.9% | -908.9% |
Income Statement
In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $131.00K | $144.00K | $109.00K | $370.00K | $1.50M | $0 | $2.20M | $3.09M | $4.60M | $4.23M |
| Cost of revenue | $0 | $5.00K | $0 | $0 | $0 | $0 | $328.00K | $482.00K | $1.03M | $956.00K |
| Gross profit | $131.00K | $139.00K | $109.00K | $370.00K | $1.50M | $0 | $1.87M | $2.61M | $3.57M | $3.27M |
| Research and development | $4.19M | $5.03M | $5.50M | $8.88M | $3.32M | $1.10M | $5.28M | $14.75M | $17.96M | $19.55M |
| Operating income | -$11.49M | -$12.62M | -$15.09M | -$17.73M | -$11.48M | -$16.83M | -$21.48M | -$27.27M | -$35.27M | -$38.58M |
| Net income | -$13.84M | -$2.49M | -$14.67M | -$17.26M | -$11.45M | -$16.83M | -$18.71M | -$26.64M | -$34.80M | -$38.45M |
| EBITDA | N/A | -$2.35M | -$14.40M | -$17.41M | -$11.31M | -$16.80M | -$20.22M | -$26.36M | -$34.01M | -$37.47M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.00K | $18.00K | $26.00K | $28.00K | $37.00K | $51.00K | $26.00K | $30.00K | $39.00K | $29.00K | $5.00K | $0 |
| Gross profit | -$5.00K | $18.00K | $26.00K | $28.00K | $37.00K | $51.00K | $26.00K | $29.00K | $37.00K | $29.00K | $5.00K | $0 |
| Operating income | -$3.32M | -$2.76M | -$2.75M | -$2.63M | -$2.92M | -$3.15M | -$2.75M | -$2.61M | -$3.39M | -$3.10M | -$3.68M | -$4.12M |
| Net income | -$475.00K | -$1.34M | -$2.69M | -$2.54M | -$2.84M | $6.85M | -$2.69M | -$2.55M | -$3.34M | -$3.04M | -$3.60M | -$3.99M |
Balance Sheet
As of Mar 2026, cash and equivalents of $5.02M were 67.9% of total assets of $7.39M, against total liabilities of $8.48M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.39M | $14.65M | $6.35M | $20.31M | $33.30M | $39.92M | $28.44M | $40.62M | $49.83M | $69.18M |
| Current assets | $6.63M | $12.13M | $3.94M | $17.05M | $29.53M | $38.40M | $28.32M | $38.57M | $46.76M | $65.09M |
| Cash and equivalents | $5.02M | $11.31M | $2.90M | $15.30M | $28.68M | $37.36M | $27.36M | $36.48M | $43.73M | $62.75M |
| Total liabilities | $8.48M | $4.16M | $2.75M | $4.98M | $3.09M | $721.00K | $1.81M | $4.33M | $5.24M | $6.82M |
| Short-term debt | N/A | $521.00K | $506.00K | $492.00K | $479.00K | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | -$1.10M | $10.49M | $3.60M | $15.33M | $30.21M | $39.20M | $26.63M | $36.30M | $44.59M | $62.36M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $9.92M | $3.85M | $7.39M | $6.96M | $9.69M | $11.98M | $14.65M | $6.96M | $9.69M | $9.47M | $6.35M | $8.88M |
| Total liabilities | $2.68M | $6.19M | $8.48M | $2.52M | $2.62M | $2.44M | $4.16M | $2.52M | $2.62M | $2.81M | $2.75M | $2.70M |
| Cash and equivalents | $8.56M | $1.67M | $5.02M | $4.29M | $6.68M | $9.05M | $11.31M | $4.29M | $6.68M | $6.19M | $2.90M | $5.29M |
| Shareholder equity | $7.24M | -$2.35M | -$1.10M | $4.44M | $7.07M | $9.54M | $10.49M | $4.44M | $7.07M | $6.66M | $3.60M | $6.18M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.83M | -$9.46M | -$14.65M | -$12.41M | -$8.45M | -$13.32M | -$14.88M | -$20.38M | -$28.86M | -$29.18M |
| Capital expenditures | $0 | $13.00K | $42.00K | $396.00K | $409.00K | $405.00K | $0 | $79.00K | $226.00K | $1.35M |
| Free cash flow | -$10.83M | -$9.47M | -$14.70M | -$12.80M | -$8.86M | -$13.73M | -$14.88M | -$20.45M | -$29.08M | -$30.54M |
| Share repurchases | $0 | $0 | $0 | $0 | $0 | $1.00K | $0 | N/A | N/A | N/A |
| Investing cash flow | $94.00K | $9.03M | $816.00K | -$966.00K | -$409.00K | -$393.00K | $747.00K | -$76.00K | -$292.00K | -$1.39M |
| Financing cash flow | $4.45M | $8.85M | $1.44M | $0 | $205.00K | $23.84M | $4.93M | $13.15M | $10.11M | $31.25M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.48M | -$3.21M | -$2.96M | -$2.38M | -$3.94M | -$2.04M | -$2.96M | -$2.64M | -$2.98M | -$2.67M | -$3.52M | -$3.15M |
| Capital expenditures | $62.00K | $23.00K | $13.00K | $0 | $0 | $0 | $13.00K | $13.00K | $0 | $0 | $0 | $27.00K |
| Free cash flow | -$2.54M | -$3.24M | -$2.98M | -$2.38M | -$3.94M | -$2.04M | -$2.98M | -$2.65M | -$2.98M | -$2.67M | -$3.52M | -$3.18M |
Frequently Asked Questions About VIVS
What is VivoSim Labs' annual revenue?
VivoSim Labs reported revenue of $131.00K for the fiscal year ended Mar 31, 2026.
How fast is VivoSim Labs' revenue growing?
Revenue was down 9.0% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -29.3%.
Is VivoSim Labs profitable?
No. VivoSim Labs reported net income of -$13.84M for the fiscal year ended Mar 31, 2026, with a net margin of -10567.2%.
How much free cash flow does VIVS generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$10.83M minus capital expenditures of $0 produced free cash flow of -$10.83M.
How much debt does VivoSim Labs have?
The balance sheet dated Mar 31, 2026 reported cash and equivalents of $5.02M.
VIVS pages: Overview, Earnings, Financials, Competitors